Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Uterine Cancer

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Cervical Cancer (122)

Cervical Cancer (122)

›

No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1	pembrolizumab + lenvatinib Sensitive: A1 - Approval pembrolizumab + lenvatinib Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
HER-2 expression	Endometrial Adenocarcinoma	HER-2 expression	Endometrial Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
NTRK1 fusion	Endometrial Cancer	NTRK1 fusion	Endometrial Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Endometrial Cancer	NTRK2 fusion	Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Endometrial Cancer	NTRK3 fusion	Endometrial Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Endometrial Cancer	No biomarker	Endometrial Cancer	cisplatin + paclitaxel + doxorubicin hydrochloride Sensitive: A2 - Guideline cisplatin + paclitaxel + doxorubicin hydrochloride Sensitive : A2	cisplatin + paclitaxel + doxorubicin hydrochloride Sensitive: A2 - Guideline cisplatin + paclitaxel + doxorubicin hydrochloride Sensitive : A2